APTAR PHARMA CO-ORGANIZES THE 6TH SYMPOSIUM ON NASAL AND PULMONARY DRUG DELIVERY IN INDIA

Louveciennes, France - October 24th, 2013 - In association with the Indian Pharmaceutical Association, Aptar Pharma, global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, co-organizes the sixth symposium on “Nasal and Pulmonary Drug Delivery” with the theme of “Global Regulatory Trends”. This symposium will be held in Mumbai, India, on October 24th and 25th, 2013.

A major biennial scientific meeting in India for sharing knowledge about Orally Inhaled and Nasal Drug Products (OINDPs)

Over 180 participants from Europe, Asia and the USA will attend this two-day scientific symposium which will focus specifically on nasal and pulmonary drug delivery. A panel of 14 highly renowned scientists and technical experts will explore and discuss the regulatory challenges facing nasal and pulmonary drug delivery systems. Symposium lectures and facilitated workshops will include:

- Dr. Steven Nichols, OINDP Consulting (UK): “Overview of the Ph. Eur”
- Dr. Tim Noakes, Mexichem Fluor (UK): “Medical Propellants: Regulatory Update and Other News”
- Mr. Richard Turner, Presspart (UK): “The Safe, Effective Containment and Delivery of pMDI Respiratory Medicines”
- Mr. Harry Peters, DFE Pharma (Germany): “Optimizing Lactose to Enhance Formulation Performance of Dry Powder Inhalers”
- Dr. Kapileswhar Swain, Wockhardt (India): “QbD Approach in the Development of Dry Powder Inhalers”
- Mr. Mark Copley, Copley Scientific (UK): “Methodologies for In Vitro Bioequivalence Testing of Generic Inhaled Products”
- Mr. David Harris, Team Consulting (UK): “Time for Change: Patient Choice and Improving Compliance”
- Mr. Stuart Wakefield, Malvern Instruments (UK): “Utilizing QbD Analytical Method Development in Nasal Spray Droplet Size Characterization”
- Dr. Sameer Updaeo, Malvern Instruments Ltd (India): “Characterization of Pharmaceutical Aerosols using Malvern Spraytec”
- Dr. Amit Misra, CDRI (India): “Inhaled Therapies for Tuberculosis in the Russian Regulatory Landscape”
- Dr. Gerallt Williams, Aptar Pharma (France): “Nasal and Pulmonary Devices: Regulatory Aspects Including Leachable and Extractable Trends”
- Dr. Julie Suman, NextBreath (USA): “Global Bioequivalence Expectations for Orally Inhaled and Nasal Drug Products”

Science really matters in OINDPs

Orally Inhaled and Nasal Drug Products are complex drug combination products.

The drug delivery device component is a sophisticated piece of engineering that typically contains ten or more components, of which the majority is high precision injection-molded plastic parts. It may also contain elastomer and metal components in the case of spray pumps and pMDIs, and even glass components for the primary drug containers in the case of nasal spray unit-doses. The successful design and development of these devices requires considerable technical and scientific resources including
expertise in Quality-by-Design and Design-for-Manufacture techniques. Aptar Pharma has invested heavily in developing strong expertise in key areas related to designing, developing and manufacturing devices for OINDPs. It includes strong technical support and added value services such as formulation science, regulatory packages, analytical chemistry, custom developments, project management and filling techniques.

Science really matters in OINDPs

Orally Inhaled and Nasal Drug Products are complex drug combination products. The drug delivery device component is a sophisticated piece of engineering that typically contains ten or more components, of which the majority is high precision injection-molded plastic parts. It may also contain elastomer and metal components in the case of spray pumps and pMDIs, and even glass components for the primary drug containers in the case of nasal spray unit-doses. The successful design and development of these devices requires considerable technical and scientific resources including expertise in Quality-by-Design and Design-for-Manufacture techniques. Aptar Pharma has invested heavily in developing strong expertise in key areas related to designing, developing and manufacturing devices for OINDPs. It includes strong technical support and added value services such as formulation science, regulatory packages, analytical chemistry, custom developments, project management and filling techniques.

A commitment to world class quality for devices produced locally in India

Building on several years of presence in India and the success of its previous scientific symposia, Aptar Pharma is proud to co-organize this 6th symposium.

Aptar Pharma is a recognized market leader in India. We serve the majority of the local pharmaceutical companies, whether they are producing OINDPs for the local market, for other Asian regions, or, as is being seen more frequently, for export into highly regulated markets.

In 2012, Aptar Pharma India opened a new Indian production facility near Mumbai to produce spray pumps and metering valves for pMDIs, furthering our commitment to provide world class quality products manufactured locally to our customers.

“Aptar Pharma is delighted to co-organize this 6th symposium with the Indian Pharmaceutical Association, continuing our long-standing collaboration to provide a platform for expert presentations and discussions about nasal and pulmonary drug delivery.”, said Kanwal Tikoo, General Manager & Vice-President, Aptar Pharma India and South East Asia. “Our invited scientific experts will be presenting to a record number of attendees this year.”

About Aptar Pharma

Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by decades of proven expertise. For more information, visit www.aptar.com/pharma

Aptargroup (NYSE: ATR) is headquartered in the US and has manufacturing sites in North America, Europe, Asia and South America. For more information, visit www.aptar.com

Aptar Pharma Press Contacts

Elisa Eschylle, Events and Press relations manager  
Tel.: +33 (0) 1 39 17 20 41 - E-mail: elisa.eschylle@aptar.com

Marion Baschet Vernet, Press attaché  
Tel.: +44 (0) 797 609 41 00 - E-mail: mbvernet@gmail.com

Delivering solutions, shaping the future.